HLX-1502
Phase 2Small molecule
HLX-1502 is one of 15 small molecule programs targeting Neurofibromatosis Type 1. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Neurofibromatosis Type 1
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Verzenio
Eli LillyApproved
Afinitor
NovartisApproved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Koselugo
AstraZenecaPhase 2
N-Acetyl Cyteien
SStanford University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HLX-1502. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHealx Limited